Inflection Biosciences Ltd

Inflection Biosciences Ltd is rated 3 out of 5 in the category biotechnology. Read and write reviews about Inflection Biosciences Ltd. Inflection Biosciences Ltd, based in Dublin and London, is developing small molecule therapeutics for the treatment of cancer. The company's pipeline of highly innovative cancer treatments were licensed from the Spanish National Cancer Research Centre (CNIO). The pipeline comprises IBL-202 (PIM/PI3K inhibitor) and IBL-300 series (PIM/PI3K/mTOR inhibitor), selected from a series of unique dual mechanism kinase inhibitors and the IBL-100 series (highly selective pan-PIM kinase inhibitors), currently in pre-clinical stages of development. Data generated to date suggests potential application in a range of haematological malignancies and treatment resistant solid tumours. Inflection Biosciences was named ‘Start-up Company of the Year’ at the 2014 Irish Pharma Awards. For more information please visit www.inflectionbio.com Inflection Biosciences Ltd总部位于都柏林和伦敦，正在开发小分子癌症治疗药物。公司的创新抗癌药产品线授权来自西班牙国立癌症研究中心(CNIO)。该产品线包括IBL-300系列（PIM/PI3K/mTOR抑制剂），选自一系列独特的双机制激酶抑制剂的IBL-202（PIM/PI3K抑制剂），以及IBL-100系列（选择性泛PIM激酶抑制剂），目前在临床前期开发阶段。现有的数据显示产品对一系列难治性实体肿瘤和血液学恶性肿瘤有潜在的应用。Inflection Biosciences在14年被爱尔兰制药奖评为年度最佳初创企业。 欲了解进一步信息，请访问www.inflectionbio.com。